Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArthroCare's bone cement delivery technology:

This article was originally published in Clinica

Executive Summary

The US FDA has given ArthroCare 510(k) clearance to sell what it claims is the industry's first fully enclosed device for mixing and delivering bone cement during vertebroplasty and kyphoplasty procedures. The Parallax integrated delivery system (IDS) uses a self-contained cement cartridge that contains precise amounts of monomer and polymer, and a mating reservoir. In addition to simplifying the cement mixing process, the device also provides precise cement volume control, a large cement reservoir that allows a vertebroplasty to be completed without refilling, and a 17-inch injection tube that minimises the operator's exposure to radiation. Current cement delivery systems often require complicated cement mixing equipment, expose the operating room staff to toxic monomer and deliver inconsistent cement mixing results, said the Austin, Texas firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel